A citation-based method for searching scientific literature

Pablo A Olivera, Juan S Lasa, Stefanos Bonovas, Silvio Danese, Laurent Peyrin-Biroulet. Gastroenterology 2020
Times Cited: 93







List of co-cited articles
710 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis.
William J Sandborn, Chinyu Su, Bruce E Sands, Geert R D'Haens, Séverine Vermeire, Stefan Schreiber, Silvio Danese, Brian G Feagan, Walter Reinisch, Wojciech Niezychowski,[...]. N Engl J Med 2017
695
27

Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme.
William J Sandborn, Julian Panés, Bruce E Sands, Walter Reinisch, Chinyu Su, Nervin Lawendy, Nana Koram, Haiyun Fan, Thomas V Jones, Irene Modesto,[...]. Aliment Pharmacol Ther 2019
86
17

Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study.
Jürgen Wollenhaupt, Eun-Bong Lee, Jeffrey R Curtis, Joel Silverfield, Ketti Terry, Koshika Soma, Chris Mojcik, Ryan DeMasi, Sander Strengholt, Kenneth Kwok,[...]. Arthritis Res Ther 2019
140
16


Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials.
William J Sandborn, Julián Panés, Geert R D'Haens, Bruce E Sands, Chinyu Su, Michele Moscariello, Thomas Jones, Ron Pedersen, Gary S Friedman, Nervin Lawendy,[...]. Clin Gastroenterol Hepatol 2019
120
16

JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects.
Shubhasree Banerjee, Ann Biehl, Massimo Gadina, Sarfaraz Hasni, Daniella M Schwartz. Drugs 2017
392
15

JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.
Daniella M Schwartz, Yuka Kanno, Alejandro Villarino, Michael Ward, Massimo Gadina, John J O'Shea. Nat Rev Drug Discov 2017
402
15


Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial.
Séverine Vermeire, Stefan Schreiber, Robert Petryka, Tanja Kuehbacher, Xavier Hebuterne, Xavier Roblin, Maria Klopocka, Adrian Goldis, Maria Wisniewska-Jarosinska, Andrey Baranovsky,[...]. Lancet 2017
247
15

Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis.
Peter C Taylor, Edward C Keystone, Désirée van der Heijde, Michael E Weinblatt, Liliana Del Carmen Morales, Jaime Reyes Gonzaga, Sergey Yakushin, Taeko Ishii, Kahaku Emoto, Scott Beattie,[...]. N Engl J Med 2017
404
13

Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib.
Kevin L Winthrop, Gil Y Melmed, Séverine Vermeire, Millie D Long, Gary Chan, Ronald D Pedersen, Nervin Lawendy, Andrew J Thorpe, Chudy I Nduaka, Chinyu Su. Inflamm Bowel Dis 2018
117
13

Analysis of Spontaneous Postmarket Case Reports Submitted to the FDA Regarding Thromboembolic Adverse Events and JAK Inhibitors.
Abril Verden, Mo Dimbil, Robert Kyle, Brian Overstreet, Keith B Hoffman. Drug Saf 2018
87
14


Venous Thromboembolism Risk With JAK Inhibitors: A Meta-Analysis.
Mark Yates, Amanda Mootoo, Maryam Adas, Katie Bechman, Sanketh Rampes, Vishit Patel, Sumera Qureshi, Andrew P Cope, Sam Norton, James B Galloway. Arthritis Rheumatol 2021
41
29

JAK selectivity for inflammatory bowel disease treatment: does it clinically matter?
Silvio Danese, Marjorie Argollo, Catherine Le Berre, Laurent Peyrin-Biroulet. Gut 2019
62
17

Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis.
William J Sandborn, Subrata Ghosh, Julian Panes, Stefan Schreiber, Geert D'Haens, Satoshi Tanida, Jesse Siffledeen, Jeffrey Enejosa, Wen Zhou, Ahmed A Othman,[...]. Gastroenterology 2020
77
14

A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis.
Katie Bechman, Sujith Subesinghe, Sam Norton, Fabiola Atzeni, Massimo Galli, Andrew P Cope, Kevin L Winthrop, James B Galloway. Rheumatology (Oxford) 2019
118
11

Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.
William J Sandborn, Subrata Ghosh, Julian Panes, Ivana Vranic, Chinyu Su, Samantha Rousell, Wojciech Niezychowski. N Engl J Med 2012
531
11

Tofacitinib Treatment Is Associated With Modest and Reversible Increases in Serum Lipids in Patients With Ulcerative Colitis.
Bruce E Sands, Pam R Taub, Alessandro Armuzzi, Gary S Friedman, Michele Moscariello, Nervin Lawendy, Ronald D Pedersen, Gary Chan, Chudy I Nduaka, Daniel Quirk,[...]. Clin Gastroenterol Hepatol 2020
45
24

Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment.
Josef S Smolen, Mark C Genovese, Tsutomu Takeuchi, David L Hyslop, William L Macias, Terence Rooney, Lei Chen, Christina L Dickson, Jennifer Riddle Camp, Tracy E Cardillo,[...]. J Rheumatol 2019
142
11

Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial.
Roy Fleischmann, Aileen L Pangan, In-Ho Song, Eduardo Mysler, Louis Bessette, Charles Peterfy, Patrick Durez, Andrew J Ostor, Yihan Li, Yijie Zhou,[...]. Arthritis Rheumatol 2019
163
11

JAK-STAT pathway targeting for the treatment of inflammatory bowel disease.
Azucena Salas, Cristian Hernandez-Rocha, Marjolijn Duijvestein, William Faubion, Dermot McGovern, Severine Vermeire, Stefania Vetrano, Niels Vande Casteele. Nat Rev Gastroenterol Hepatol 2020
151
11

Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis.
Stephen Hanauer, Remo Panaccione, Silvio Danese, Adam Cheifetz, Walter Reinisch, Peter D R Higgins, Deborah A Woodworth, Haiying Zhang, Gary S Friedman, Nervin Lawendy,[...]. Clin Gastroenterol Hepatol 2019
83
12

Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis.
Bruce E Sands, William J Sandborn, Remo Panaccione, Christopher D O'Brien, Hongyan Zhang, Jewel Johanns, Omoniyi J Adedokun, Katherine Li, Laurent Peyrin-Biroulet, Gert Van Assche,[...]. N Engl J Med 2019
371
10

Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis.
Jeffrey R Curtis, Fenglong Xie, Huifeng Yun, Sasha Bernatsky, Kevin L Winthrop. Ann Rheum Dis 2016
146
10


Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial.
Mark C Genovese, Kenneth Kalunian, Jacques-Eric Gottenberg, Neelufar Mozaffarian, Beatrix Bartok, Franziska Matzkies, Jie Gao, Ying Guo, Chantal Tasset, John S Sundy,[...]. JAMA 2019
127
10

Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis.
Peter C Taylor, Michael E Weinblatt, Gerd R Burmester, Terence P Rooney, Sarah Witt, Chad D Walls, Maher Issa, Claudia A Salinas, Chadi Saifan, Xin Zhang,[...]. Arthritis Rheumatol 2019
79
12

Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials.
Julian Panés, William J Sandborn, Stefan Schreiber, Bruce E Sands, Séverine Vermeire, Geert D'Haens, Remo Panaccione, Peter D R Higgins, Jean-Frederic Colombel, Brian G Feagan,[...]. Gut 2017
197
10

Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.
Ronald F van Vollenhoven, Roy Fleischmann, Stanley Cohen, Eun Bong Lee, Juan A García Meijide, Sylke Wagner, Sarka Forejtova, Samuel H Zwillich, David Gruben, Tamas Koncz,[...]. N Engl J Med 2012
614
9

Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.
Mark C Genovese, Roy Fleischmann, Bernard Combe, Stephen Hall, Andrea Rubbert-Roth, Ying Zhang, Yijie Zhou, Mohamed-Eslam F Mohamed, Sebastian Meerwein, Aileen L Pangan. Lancet 2018
198
9

Vedolizumab as induction and maintenance therapy for ulcerative colitis.
Brian G Feagan, Paul Rutgeerts, Bruce E Sands, Stephen Hanauer, Jean-Frédéric Colombel, William J Sandborn, Gert Van Assche, Jeffrey Axler, Hyo-Jong Kim, Silvio Danese,[...]. N Engl J Med 2013
9

Systematic review with meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease.
Christopher Ma, Jeffrey K Lee, Anish R Mitra, Anouar Teriaky, Daksh Choudhary, Tran M Nguyen, Niels Vande Casteele, Reena Khanna, Remo Panaccione, Brian G Feagan,[...]. Aliment Pharmacol Ther 2019
45
20

Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis.
Bruce E Sands, Laurent Peyrin-Biroulet, Edward V Loftus, Silvio Danese, Jean-Frédéric Colombel, Murat Törüner, Laimas Jonaitis, Brihad Abhyankar, Jingjing Chen, Raquel Rogers,[...]. N Engl J Med 2019
261
9

The safety of vedolizumab for ulcerative colitis and Crohn's disease.
Jean-Frédéric Colombel, Bruce E Sands, Paul Rutgeerts, William Sandborn, Silvio Danese, Geert D'Haens, Remo Panaccione, Edward V Loftus, Serap Sankoh, Irving Fox,[...]. Gut 2017
440
9

Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial.
Gerd R Burmester, Joel M Kremer, Filip Van den Bosch, Alan Kivitz, Louis Bessette, Yihan Li, Yijie Zhou, Ahmed A Othman, Aileen L Pangan, Heidi S Camp. Lancet 2018
172
9

Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases.
James D Clark, Mark E Flanagan, Jean-Baptiste Telliez. J Med Chem 2014
286
9

Janus kinases in immune cell signaling.
Kamran Ghoreschi, Arian Laurence, John J O'Shea. Immunol Rev 2009
701
9

Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease.
William J Sandborn, Brian G Feagan, Edward V Loftus, Laurent Peyrin-Biroulet, Gert Van Assche, Geert D'Haens, Stefan Schreiber, Jean-Frederic Colombel, James D Lewis, Subrata Ghosh,[...]. Gastroenterology 2020
78
11

Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial.
Brian G Feagan, Silvio Danese, Edward V Loftus, Séverine Vermeire, Stefan Schreiber, Timothy Ritter, Ronald Fogel, Rajiv Mehta, Sandeep Nijhawan, Radosław Kempiński,[...]. Lancet 2021
54
16

Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.
Brian G Feagan, William J Sandborn, Christopher Gasink, Douglas Jacobstein, Yinghua Lang, Joshua R Friedman, Marion A Blank, Jewel Johanns, Long-Long Gao, Ye Miao,[...]. N Engl J Med 2016
867
8


Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis.
Philip Mease, Stephen Hall, Oliver FitzGerald, Désirée van der Heijde, Joseph F Merola, Francisco Avila-Zapata, Dorota Cieślak, Daniela Graham, Cunshan Wang, Sujatha Menon,[...]. N Engl J Med 2017
261
8

Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study.
Maxime Dougados, Désirée van der Heijde, Ying-Chou Chen, Maria Greenwald, Edit Drescher, Jiajun Liu, Scott Beattie, Sarah Witt, Inmaculada de la Torre, Carol Gaich,[...]. Ann Rheum Dis 2017
218
8

Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial.
Gerd R Burmester, Ricardo Blanco, Christina Charles-Schoeman, Jürgen Wollenhaupt, Cristiano Zerbini, Birgitta Benda, David Gruben, Gene Wallenstein, Sriram Krishnaswami, Samuel H Zwillich,[...]. Lancet 2013
466
8

Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors.
Dafna Gladman, William Rigby, Valderilio F Azevedo, Frank Behrens, Ricardo Blanco, Andrzej Kaszuba, Elizabeth Kudlacz, Cunshan Wang, Sujatha Menon, Thijs Hendrikx,[...]. N Engl J Med 2017
249
8

Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials.
Stanley B Cohen, Yoshiya Tanaka, Xavier Mariette, Jeffrey R Curtis, Eun Bong Lee, Peter Nash, Kevin L Winthrop, Christina Charles-Schoeman, Krishan Thirunavukkarasu, Ryan DeMasi,[...]. Ann Rheum Dis 2017
227
8

Mechanisms and consequences of Jak-STAT signaling in the immune system.
Alejandro V Villarino, Yuka Kanno, John J O'Shea. Nat Immunol 2017
514
8


Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial.
Désirée van der Heijde, Xenofon Baraliakos, Lianne S Gensler, Walter P Maksymowych, Vira Tseluyko, Oleg Nadashkevich, Walid Abi-Saab, Chantal Tasset, Luc Meuleners, Robin Besuyen,[...]. Lancet 2018
126
8


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.